Zobrazeno 1 - 10 of 42 pro vyhledávání: '"N. C. Allan"'
1
Thioguanine used in maintenance therapy of chronic myeloid leukaemia causes non-cirrhotic portal hypertension. Results from MRC CML. II. Trial comparing busulphan with busulphan and thioguanine
Autor: Richard Gray, N. C. Allan, J. Fooks, Patricia Shepherd
Portal hypertension with varices developed in 18/675 patients with chronic myeloid leukaemia (CML) in a randomized trial comparing busulphan with busulphan and thioguanine. All 18 had received the drug combination and none busulphan alone (P less tha
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75561575851aebf6ff8a0229fed0d9a5
https://ora.ox.ac.uk/objects/uuid:cfab1dab-d98b-4274-b548-a184ee117110
Zobrazit plný text záznamu
2
Folic Acid and the Pill
Autor: A. H. Goldstone, J. K. Wood, N. C. Allan
Publikováno v: Scandinavian Journal of Haematology. 9:539-544
3 cases of folic acid deficient megaloblastic anaemia were described by this article in which a combined oral contraceptive was etiologically implicated. In Case I a 22 year old woman with a 6-month history of increasing tiredness was examined. 6 wee
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0be5ce729476a2959704f50bb460c21e
https://doi.org/10.1111/j.1600-0609.1972.tb00981.x
Zobrazit plný text záznamu
3
Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission
Autor: Nicholas C. P. Cross, Andreas Reiter, J. M. Goldman, M. Emig, R. Hehlmann, Jaspal Kaeda, U. Berger, P. C. A. Shepherd, A. Reichert, S. Saussele, Andreas Hochhaus, Beate Schultheis, N. C. Allan
Publikováno v: Blood. 95:62-66
A substantial minority of patients with chronic myelogenous leukemia (CML) achieve a complete response (CR) to treatment with interferon- (IFN), defined as the disappearance of Philadelphia chromosome-positive metaphases. Currently it is unclear h
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::709786f6822227a888f917f643cbd399
https://doi.org/10.1182/blood.v95.1.62
Zobrazit plný text záznamu
4
Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival
Autor: Patricia Shepherd, N. C. Allan, Ruth Suffolk, Jim Halsey
Publikováno v: British Journal of Haematology. 89:546-554
Two hundred and nineteen cases of Ph+ve CML and 15 Ph-ve, BCR+ve CML cases have been analysed to determine the breakpoint site and its relationship to clinical features, cytogenetic response, duration of chronic phase and survival. 119 cases have had
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8c2b43ecf0cd08e4db8c2a49950786f
https://doi.org/10.1111/j.1365-2141.1995.tb08362.x
Zobrazit plný text záznamu
5
Severe cytopenias associated with the sequential use of busulphan and interferon-alpha in chronic myeloid leukaemia
Autor: Susan M. Richards, N. C. Allan, Patricia Shepherd
Publikováno v: British Journal of Haematology. 86:92-96
We describe four patients who developed severe thrombocytopenia which progressed to aplasia after the use of alpha-interferon in maintenance therapy of chronic phase CML after busulphan induction. On reviewing over 400 patients in the MRC CML III tri
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05d04661fa408425a49d94464d000430
https://doi.org/10.1111/j.1365-2141.1994.tb03257.x
Zobrazit plný text záznamu
7
Primary ileocecal lymphoma. A study of 22 patients
Autor: Martin J. Auger, N. C. Allan
Publikováno v: Cancer. 65:358-361
Twenty-two patients with primary ileocecal non-Hodgkin's lymphoma were reviewed. Abdominal pain (67%), altered bowel habits (50%), and weight loss (50%) were the most common presenting symptoms and an abdominal mass was palpable in 50%. Sixteen (73%)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::90560bede89393197f655932d5b81b94
https://doi.org/10.1002/1097-0142(19900115)65:2<358::aid-cncr2820650230>3.0.co
Zobrazit plný text záznamu
9
A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group
Autor: Joerg Hasford, J. C. Kluin-Nelemans, N. C. Allan, Michele Baccarani, H. Ansari, Markus Pfirrmann, Guiliana Alimena, Juan Luis Steegmann, Rüdiger Hehlmann
Publikováno v: Journal of the National Cancer Institute. 90(11)
BACKGROUND: Interferon alfa is a conservative and widely used alternative to bone marrow transplantation in treatment of patients with early chronic myeloid leukemia (CML). A meta-analysis was conducted to develop a reliable prognostic scoring system
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b27f5fb77f046a989ae9554851504bd7
https://pubmed.ncbi.nlm.nih.gov/9625174
Zobrazit plný text záznamu
10
Progress with interferon in CML--results of the MRC UK CML III study
Autor: P C, Shepherd, S M, Richards, N C, Allan
Publikováno v: Bone marrow transplantation. 17
527 patients with CML were entered into the multicentre randomised MRC CML III study comparing IFN-alpha n1 to standard chemotherapy, either busulphan or hydroxyurea. Haematologic response to IFN as assessed by the level of control of the WCC predict
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::fb50d63d14d07b0c0fe6e4332033c92c
https://pubmed.ncbi.nlm.nih.gov/8769693
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje